Charles York focuses his practice on the representation of both issuers and underwriters on a broad range of capital markets transactions, including initial public offerings and other public and private equity offerings, as well as high-yield, investment-grade and convertible debt issuances. Charles also regularly advises clients on general corporate matters, including SEC reporting and corporate governance.
Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.
Immunology Company argenx Announces $1.27 Billion Global Offering
July 26, 2023
Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.
NewAmsterdam Pharma – $181.6 Million Follow-on Offering
June 6, 2023
Cooley advised the underwriters in NewAmsterdam Pharma’s $181.6 million follow-on offering. NewAmsterdam is a clinical-stage biopharmaceutical company with a mission to improve care of patients with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. Lawyers Eric Blanchard, Div Gupta, Jean Park, Minkyu Park, Charles York, and Katie Lapidus led the Cooley team.
Olink Holding AB – $116.6 Million Follow-on Offering
January 18, 2023
Cooley advised the underwriters in Olink Holding AB’s $116.6 million follow-on offering. Olink is a company dedicated to working with the scientific community on accelerating proteomics across multiple disease areas to enable new discoveries and improve the lives of patients. Lawyers Eric Blanchard, Charlie Kim, Minkyu Park, Ryan Walker, Katie Lapidus, Megan Taing and Charles York led the Cooley team.
Karuna Therapeutics – $862.5 Million Follow-on Offering
September 7, 2022
Cooley advised the underwriters in Karuna Therapeutics’ $862.5 million follow-on offering of 4,011,628 shares of common stock at a public offering price of $215 per share. Karuna is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Partners Richard Segal, Jean Park, Div Gupta and associate Darah Protas led the Cooley team.
